Top Markets
Coin of the day
Enimmune corporation Enimmune corporation

Enimmune corporation

6564
Classement en actions #26781
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused... Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
Prix de l'action
$0.52468396
Capitalisation boursière
$37.85M
Changement (1 jour)
1.23%
Changement (1 an)
-4.53%
Pays
TW
Échange Enimmune corporation (6564)

Catégorie

Ratio P/B pour Enimmune corporation (6564)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Enimmune corporation, le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Enimmune corporation de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH